Regeneron Pharmaceuticals (REGN)

Revenue surged 17% as Dupixent and EYLEA HD posted record sales.

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 11% to $14.29, while non-GAAP net income reached $1.5 billion. Chief

Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billi...

Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know. Regeneron beat analysts’ reven...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

All three can be bought on the dip.

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

It might pull it off, provided several things fall right in place.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

There could be additional catalysts for this drugmaker over the next year.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Check out the companies making headlines this week: Toll Brothers (NYSE:TOL): Homebuilding company Toll Brothers (NYSE:TOL) rose by 8.3% on Wednesday after t...